CTTC’s Calmare therapy effective against discomfort associated with chemotherapy-induced peripheral neuropathy Competitive Technology, Inc. The article published in the Journal of Discomfort and Symptom Management ( detailed the scholarly study led by principal investigator, Thomas J. Smith, M silagra-rx.com .D., Endowed Seat of Palliative Care Study and Medical Director of the Thomas Palliative Treatment Device Virginia Commonwealth University’s Massey Malignancy Center. Calmare, which treats chronic oncologic and neuropathic pain, received FDA certification for product sales in the U.S. In 2009 2009.S. Independent clinical study, to particularly examine the power of CTTC’s Calmare discomfort therapy treatment to diminish pain connected with CIPN.
today reported latest accomplishments and financial results for the fourth one fourth and season ended December 31, 2010. We are pleased with the progress made on our pixantrone MAA in Europe because it was validated in December 2010, and as it undergoes energetic review.S. Meals and Medication Administration’s Office of New Medications to discuss our appeal to the FDA for our New Drug Software for pixantrone as well concerning reach final contract on the look and regulatory utility of our prepared pivotal trial, said James A. Bianco, M.D., CEO of the Company. These developments coupled with our initiatives to increase our pipeline by in-licensing a novel stage III drug candidate promise to help make the next several months exciting.